Your session is about to expire
← Back to Search
Isatuximab for Amyloidosis
Study Summary
This trial is testing the effects of isatuximab on patients with high-risk AL amyloidosis. Isatuximab is an antibody that may stop tumor cells from growing and spreading.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 307 Patients • NCT02990338Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My diagnosis of amyloidosis was confirmed through specific tests on my tissue samples.
- Group 1: Treatment (isatuximab, chemotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other experimental studies involving Isatuximab?
"Currently, 1322 live clinical studies into Isatuximab exist with 270 of them in their final phase. To further illustrate the scope of these trials, there are 42902 sites offering access to this medication - many of which being located in Philadelphia, Pennsylvania."
Is Isatuximab generally tolerated by patients without major side effects?
"The safety of Isatuximab is believed to be relatively low, as this Phase 1 trial only has limited evidence backing its efficacy and security. Thus, our team at Power assigned it a score of 1."
In what geographic areas is this medical research being conducted?
"This trial is running out of Columbia University in the city of New york, Emory University Hospital Midtown located in Dallas and UT Southwestern situated in Orange along with 6 additional sites."
Is this research initiative still accepting participants?
"Affirmative. A review of the clinical trials website reveals that this research project, first posted on April 28th 2021 is currently recruiting participants. 25 individuals are required from 6 separate medical facilities."
What conditions usually warrant the administration of Isatuximab?
"Isatuximab is typically used to alleviate synovitis, however it can be prescribed as a form of treatment for ophthalmia, sympathetic diseases, and certain forms of lung cancer or branch retinal vein occlusion."
Share this study with friends
Copy Link
Messenger